AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29326015
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin administered in the arm
Trial: 22741618
Drug: Artemisinin-piperaquine (Artequick®)
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-piperaquine (Artequick®) - 2.8 mg/kg artemisinin plus 17.1 mg/kg piperaquine per day for 2 days
Trial: 22741618
Drug: Artesunate-amodiaquine (Coarsucam™)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine (Coarsucam™) - 4.7 mg/kg artesunate plus 12.6 mg/kg amodiaquine per day for 3 days
Trial: 17459695
Drug: Ketorolac 15
RxNorm normalized name: ketorolac 15.75 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 15 mg i.v. bolus 20 min before induction, followed by an infusion of 7.5 mg/h
Trial: 10095154
Drug: Octreotide 25
RxNorm normalized name: octreotide 2500 mcg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 25 microgram/h intravenously (continuous infusion)
Trial: 10095154
Drug: Octreotide 100
RxNorm normalized name: 1 ML octreotide 100 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 100 microgram/h intravenously (continuous infusion)
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy at 4 months after surgery for pre/perimenopausal patients
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy at 7 months after surgery for pre/perimenopausal patients
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy at 2 months after surgery for postmenopausal patients
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy at 4 months after surgery for postmenopausal patients
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy after three or six cycles of CMF for pre/perimenopausal women
Trial: 8690630
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy after no cycles or three cycles of CMF for postmenopausal women
Trial: 31652220
Drug: Red LED
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red LED photomodulation (633 nm) for 20 minutes at 4 weekly sessions (105 mW/cm, 126 J/cm)
Trial: 28784510
Drug: Synbiotic beverage
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic beverage (150mL daily)
Trial: 28784510
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage (150mL daily)
Trial: 25660828
Drug: Wearable pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable pulsed electromagnetic field (PEMF) therapy device
Trial: 19775034
Drug: Opioid-sparing postoperative
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-sparing postoperative analgesia protocol (tramadol patient‐controlled analgesia, parecoxib and rescue‐only morphine)
Trial: 19775034
Drug: Standard morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard morphine patient‐controlled analgesia
Trial: 17288687
Drug: EPs 7630
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs 7630 solution (30 drops three times daily for 7 days)
Trial: 12807337
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 drops three times daily for 7 days)
Trial: 17288687
Drug: EPs 7630
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs 7630 solution
Trial: 8819128
Drug: Intralesional GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional GM-CSF (15-50 mg doses)
Trial: 20041960
Drug: Conventional hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hemodialysis (CvHD) thrice weekly for 6 months
Trial: 15661451
Drug: High TSH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TSH values (TSH >= 10 mU/L)
Trial: 15661451
Drug: Normal TSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal TSH values (0.2-4 mU/L)
Trial: 12067084
Drug: Real acupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acupuncture treatment (three times per week for four weeks)
Trial: 12067084
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment (three times per week for four weeks)
Trial: 15321137
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/ml (group B)
Trial: 15321137
Drug: Bupivacaine 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml (group BS)
Trial: 15321137
Drug: Bupivacaine 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml + epinephrine 1 microg/ml (group BSE)
Trial: 7734157
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice a day (Group A)
Trial: 7734157
Drug: Ciprofloxacin drops
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin drops in saline solution locally twice a day (Group B)
Trial: 2291745
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (P)
Trial: 2291745
Drug: Control preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control preparation (R)
Trial: 21842003
Drug: 1-stage early
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-stage early loaded implants
Trial: 21842003
Drug: 2-stage early
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-stage early loaded implants
Trial: 20715726
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of lactated Ringer's solution (20 ml.kg(‐1), n=40)
Trial: 20715726
Drug: 4% succinylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% succinylated gelatin solution (500 ml, n=40)
Trial: 20715726
Drug: Ephedrine infusion
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine infusion (1.25 mg.minute(‐1)) plus lactated Ringer's solution (1000 ml, n=40)
Trial: 20715726
Drug: Ephedrine infusion
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine infusion with crystalloid co-load
Trial: 17396039
Drug: irinotecan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 80 mg/m2 followed by FA 500 mg/m2 and 5-FU 2,000 mg/m2 24 h weekly for 6 weeks
Trial: 17396039
Drug: irinotecan 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 125 mg/m2 weekly for 4 weeks
Trial: 11952192
Drug: Behavioral couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couples therapy (BCT; n = 37)
Trial: 11952192
Drug: Individual-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-based treatment (IBT; n = 38)
Trial: 8561836
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg cycloserine
Trial: 8561836
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cycloserine
Trial: 8561836
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg cycloserine
Trial: 2230895
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy (Control) (n = 198)
Trial: 26262795
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (7.5 g of 1% testosterone gel daily for 3 years)
Trial: 26262795
Drug: Placebo (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gel packets daily for 3 years)
Trial: 19210644
Drug: Suplatast tosilate
RxNorm normalized name: Edoxaban Tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suplatast tosilate (6 mg/kg daily)
Trial: 19210644
Drug: Ketotifen fumarate
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen fumarate (0.06 mg/kg daily)
Trial: 15034704
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg once daily for 7 days
Trial: 11142548
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for generalized anxiety disorder (GAD)
Trial: 24838406
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n=201)
Trial: 20370938
Drug: Dietary group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary group (DG) receiving daily 1200 mg Ca and 7.5 microg vitamin D3 for the first 12 months, then 1200 mg Ca and 22.5 microg vitamin D3 for the next 18 months through fortified dairy products
Trial: 18840700
Drug: Stuttering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering treatment efficacy research
Trial: 10217232
Drug: rBPI21 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBPI21 (4 mg x kg(‐1) x d(‐1) for 2 consecutive days)
Trial: 10217232
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent volume by continuous infusion)
Trial: 80219
Drug: Perhexiline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perhexiline (300 to 400 mg per day)
Trial: 30205115
Drug: Genotype-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided warfarin dosing (CYP2C9, VKORC1, and CYP4F2)
Trial: 30205115
Drug: Clinical-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-guided warfarin dosing
Trial: 24890623
Drug: 2L-PEG preparations
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L-PEG preparations
Trial: 24890623
Drug: 2-glasses solutions
RxNorm normalized name: Red arsenic glass
DrugBank: Tetraarsenic tetrasulfide (DB19141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-glasses solutions
Trial: 24890623
Drug: 4L-PEG preparations
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L-PEG preparations
Trial: 20206571
Drug: Pulsed dose-rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dose-rate (PDR) brachytherapy with optimized dose distribution
Trial: 20206571
Drug: Iridium wires
RxNorm normalized name: iridium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iridium wires (traditional treatment)
Trial: 18608313
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy combined with imipramine
Trial: 18608313
Drug: Graded in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded in vivo exposure treatment combined with imipramine
Trial: 18608313
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment combined with imipramine
Trial: 18608313
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy combined with imipramine
Trial: 18608313
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy combined with placebo
Trial: 18608313
Drug: Graded in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded in vivo exposure treatment combined with placebo
Trial: 18608313
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment combined with placebo
Trial: 18608313
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy combined with placebo
Trial: 10659548
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg levofloxacin
Trial: 8680689
Drug: L-NAME (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (nonselective NOS inhibitor)
Trial: 8680689
Drug: Aminoguanidine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoguanidine (selective inhibitor of inducible NOS)
Trial: 30763138
Drug: Sol-Gel Silica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sol-Gel Silica Infiltration (SG)
Trial: 28373993
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/day (group A, n = 31)
Trial: 26071673
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (COC)
Trial: 10090432
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg oral loading dose followed by 200 mg/d for 10 days)
Trial: 10090432
Drug: Comparator therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator therapies (erythromycin, cefaclor, ofloxacin, clarithromycin, and ciprofloxacin)
Trial: 10090432
Drug: Comparator therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator therapies
Trial: 7727835
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17‐propionate preparation under occlusion
Trial: 7727835
Drug: Corticoid‐free cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticoid‐free cream under occlusion
Trial: 7727835
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment and occlusion (aluminium chamber)
Trial: 7727835
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment and no occlusion
Trial: 6873608
Drug: Loperamide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (6 mg at 5 h and at 30 min before the meal)
Trial: 27385022
Drug: Tolvaptan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (15 mg) with fixed dose of diuretics
Trial: 27385022
Drug: Tolvaptan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (15 mg) with half-dose of diuretics
Trial: 27385022
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Tolvaptan with fixed dose and half-dose of diuretics)
Trial: 15194017
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus simvastatin 10 mg
Trial: 15194017
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus simvastatin 20 mg
Trial: 15194017
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus simvastatin 40 mg
Trial: 9311407
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 2.1 ml/h (low rate group)
Trial: 9311407
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 6.3 ml/h (high rate group)
Trial: 7506178
Drug: Nimesulide 50
RxNorm normalized name: nimesulide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 50 mg/dose
Trial: 7506178
Drug: Lysine-acetylsalicylate 720
RxNorm normalized name: Acetylsalicylate
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine-acetylsalicylate 720 mg/dose
Trial: 2882339
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (subcutaneous calcium heparin, 12,500 IU daily)
Trial: 2882339
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual therapy)
Trial: 28581346
Drug: Online cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive-behavioral therapy group program - 'Recapture Life'
Trial: 9218069
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m. (OME20)
Trial: 9218069
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg o.m. (OME10)
Trial: 9218069
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.d. (RAN)
Trial: 9218069
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg weekends (OMEW)
Trial: 3661107
Drug: Ketanserin 10
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 10 mg i.v.
Trial: 3661107
Drug: Droperidol 5
RxNorm normalized name: droPERidol 5 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5 mg i.v.
Trial: 3661107
Drug: Hydergine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine 0.9 mg i.v.
Trial: 24631589
Drug: LY545694 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 (2 doses)
Trial: 24631589
Drug: LY545694 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 (3 doses)
Trial: 24631589
Drug: LY545694 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 (all doses)
Trial: 19930764
Drug: 5-6 g
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-6 g beta-glucan
Trial: 19930764
Drug: 8-9 g
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-9 g beta-glucan
Trial: 16914415
Drug: Subcutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous suture line (Group A2)
Trial: 14696461
Drug: Interferon Alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon Alfa-2a (4.5 million units daily for 16 weeks) plus Lamivudine (100 mg daily starting from week 5 for 48 weeks)
Trial: 14696461
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg daily for 48 weeks)
Trial: 8649661
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent chlorhexidine solution applied with an interdental brush
Trial: 8649661
Drug: 0.1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 percent quinine solution (control) applied with an interdental brush
Trial: 8649661
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent chlorhexidine solution
Trial: 8649661
Drug: 0.1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 percent quinine solution (control)
Trial: 1434863
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of fentanyl citrate